Tiny Implant Wipes Out Bladder Cancer in 82% of Patients
- A new targeted drug delivery system called TAR-200 has shown remarkable results in a phase 2 clinical trial, eliminating tumors in 82% of patients with high-risk non-muscle-invasive bladder...
- In most cases, the cancer disappeared within three months of therapy, and nearly half of the patients remained cancer-free one year later.
- "Traditionally, these patients have had very limited treatment options.
“`html
TAR-200: Novel Drug Delivery System Achieves High Remission Rate in Bladder Cancer Trial
Table of Contents
Updated November 12, 2025, 11:08:53 PST
Breakthrough Results in Phase 2 Trial
A new targeted drug delivery system called TAR-200 has shown remarkable results in a phase 2 clinical trial, eliminating tumors in 82% of patients with high-risk non-muscle-invasive bladder cancer that had resisted prior treatment.
In most cases, the cancer disappeared within three months of therapy, and nearly half of the patients remained cancer-free one year later. These results represent a notable advancement in treating a challenging form of bladder cancer.
“Traditionally, these patients have had very limited treatment options. This new therapy is the most effective one reported to date for the most common form of bladder cancer,” said Sia Daneshmand,MD,director of urologic oncology at Keck Medicine of USC and lead author of the study,which was published in the Journal of Clinical Oncology on October 20,2024 (“TAR-200 Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer”). “The findings of the clinical trial are a breakthrough in how certain types of bladder cancer might be treated, leading to improved outcomes and saved lives.”
How the TAR-200 System Works
The TAR-200 device is a small,pretzel-shaped implant designed to hold the chemotherapy drug gemcitabine. It’s approximately 1.5 cm in length and is made of a biocompatible material. The device is inserted into the bladder using a catheter, a minimally invasive procedure, where it gradually releases the drug over the course of three weeks in each treatment cycle.
Traditionally, gemcitabine has been delivered as a liquid solution that remains in the bladder for only a few hours, which limited its effectiveness in killing cancer cells, said Daneshmand, who is also a member of the USC Norris Comprehensive Cancer Center. This short contact time often necessitates frequent and intensive treatments, leading to significant side effects for patients.
“The theory behind this study was that the longer the medicine sits inside the bladder, the more deeply it would penetrate the tumor and the more cancer cells it would kill,” explained Daneshmand in a USC News article published October 26, 2024.
Understanding Non-muscle-invasive Bladder Cancer
non-muscle-invasive bladder cancer (NMIBC) is the most common type of bladder cancer, accounting for approximately 80% of all cases, according to the American Cancer Society. It’s characterized by cancer cells that haven’t grown into the deeper muscle layers of the bladder wall.
High-risk NMIBC refers to cases with a higher likelihood of progressing to